Aiforia Technologies Downgraded to 'Hold' Following Profit Warning

Aiforia Technologies Oyj has experienced a significant downturn, prompting NuWays AG to downgrade its stock recommendation to 'Hold'. The company's revenue for the first half of 2026 plummeted to €0.75 million, a 46% year-on-year drop from the prior year's €1.4 million. This decline contrasts with the expected year-on-year doubling, following strong clinical growth in 2025.

The decrease in revenue is attributed to a lack of onboarding revenues and reduced usage of Aiforia's solutions. Only one new clinical client was secured in H1'26, with existing client relationships not contributing substantial new revenue. Research revenue also declined notably.

Projected full-year 2026 revenue is now €2.1 million, down from the previous estimate of €6 million, with anticipated losses increasing. Though a capital increase and loan provide some financial leeway, concerns remain over funding sustainability.